

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Acetazolamide

Acetazolamide sodium

January 10, 2024

Therapeutic category

Diuretics

Non-proprietary name

Acetazolamide

Acetazolamide sodium

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions):

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Acute respiratory distress syndrome, pulmonary oedema</u> <u>If rapidly progressive dyspnoea, hypoxaemia, or chest X-ray</u> <u>abnormalities such as diffuse infiltrative shadow in both lungs are</u> <u>observed, administration of this drug should be discontinued, and</u> <u>appropriate measures should be taken.</u>

Note: Designated as drugs requiring preparation of a Drug Guide for Patients

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp